What is Hedera-22?
Founded in 2015 and headquartered in Liège, Belgium, Hedera-22 operates at the critical intersection of environmental microbiology and bioinformatics. The company specializes in the discovery of novel biomolecules, targeting high-value applications in both human medicine and the agro-industry. By utilizing advanced computational models to analyze complex biological data, Hedera-22 effectively streamlines the identification of therapeutic and industrial compounds that were previously difficult to isolate.
The company's market position is defined by its ability to translate academic breakthroughs into scalable commercial solutions. As a key player in the Belgian biotech ecosystem, Hedera-22 serves as a bridge between fundamental scientific inquiry and practical, market-ready innovation, addressing urgent needs for sustainable and effective biomolecular solutions.
How much funding has Hedera-22 raised?
Hedera-22 has raised a total of $2.2M across 1 funding round:
Other Financing Round
$2.2M
Other Financing Round (2024): $2.2M with participation from Gesval, Aravis, and Noshaq
Key Investors in Hedera-22
Gesval
Gesval S.A. is an entity associated with the University of Liège, dedicated to managing and commercializing intellectual property through licensing and the incubation of spin-off companies.
Aravis
Aravis SA is a Zurich-based private equity firm specializing in high-tech growth investments, providing both capital and strategic expertise to scale companies in the biotech and industrial sectors.
Noshaq
Noshaq is a Liège-based investment fund that acts as a catalyst for territorial transition, providing comprehensive financing solutions to support the growth and sustainability of regional enterprises.
What's next for Hedera-22?
With the recent infusion of capital, Hedera-22 is poised to transition into a phase of rapid scaling and commercial deployment. The strategic roadmap focuses on enhancing its bioinformatics platform to increase the throughput of biomolecule discovery, thereby reducing the time-to-market for potential medical and agricultural products. Furthermore, the company is expected to deepen its collaborative efforts with industrial partners to validate its findings in real-world settings.
The long-term outlook for Hedera-22 remains robust, as the firm continues to attract high-caliber institutional backing. By maintaining its focus on high-impact research and strategic partnerships, the company is well-equipped to navigate the complexities of the biotech landscape and deliver significant value to its stakeholders while advancing the frontiers of environmental and medical science.
